Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
43 hedge funds and large institutions have $140M invested in Mirati Therapeutics, Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 44 → 43 (-1)
14% less capital invested
Capital invested by funds: $162M → $140M (-$22M)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
29% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$1.74M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$1.19M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$560K |
| 4 |
IAM
Integre Asset Management
New York
|
+$425K |
| 5 |
State Street
Boston,
Massachusetts
|
+$116K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$3M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.37M |
| 3 |
Goldman Sachs
New York
|
-$246K |
| 4 |
Jane Street
New York
|
-$244K |
| 5 |
SIM
Spark Investment Management
New York
|
-$231K |
MRTX Hedge Fund Activity: Q3 2014 in Review
43 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q3 2014, worth a combined $140M — down 14% from $162M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of MRTX and 6 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 10 added.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $1.74M. The largest seller was Franklin Resources, cutting an estimated $3M.
- 43 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q3 2014, down from 44 in Q2 2014.
- Funds reported $140M of Mirati Therapeutics, Inc. Common Stock stock for Q3 2014, down 14% quarter-over-quarter.
- 6 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q3 2014 and 7 closed out, a net change of -1 holder.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q3 2014 was JP Morgan Chase, an estimated $1.74M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q3 2014 was Franklin Resources, an estimated $3M sold.
Based on aggregated 13F filings for Q3 2014.